Cue Biopharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the certified results of the 2022 Annual Meeting of Stockholders held by Cue Biopharma, Inc. on June 9, 2022. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol CUE.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Stockholders voted on the election of seven director nominees and the ratification of the independent auditor. All director nominees were elected, though some received significant "withheld" votes. The appointment of RSM US LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, was ratified.
| Director Nominee | For Votes | Withheld Votes | Broker Non-Votes |
|---|---|---|---|
| Frederick Driscoll | 8,034,828 | 3,896,002 | 14,293,960 |
| Aaron Fletcher | 11,592,871 | 337,959 | 14,293,960 |
| Cameron Gray | 11,729,550 | 201,280 | 14,293,960 |
| Tamar Howson | 9,980,282 | 1,950,548 | 14,293,960 |
| Peter Kiener | 11,695,965 | 234,865 | 14,293,960 |
| Frank Morich | 7,782,828 | 4,148,002 | 14,293,960 |
| Daniel R. Passeri | 11,844,942 | 85,888 | 14,293,960 |
Auditor Ratification Results:
- For: 26,125,468
- Against: 32,428
- Abstain: 66,895
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to calculate the percentage of votes withheld for directors Frederick Driscoll and Frank Morich, who received the highest opposition.
- Confirm the total number of shares entitled to vote at the meeting to understand the significance of the 14,293,960 broker non-votes recorded for each director nominee.
- Review the Proxy Statement filed on April 29, 2022, for detailed biographies of the elected directors and the rationale for the auditor appointment.